Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

Insulin-induced hypoglycemia is a major treatment barrier in type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon. Varying glucose over the range of concentrations that occur physiologically between the fed and fuel-depri...

Full description

Bibliographic Details
Main Authors:	Kim, A, Knudsen, J, Madara, J, Benrick, A, Hill, T, Abdul Kadir, L, Kellard, J, Mellander, L, Miranda, C, Lin, H, James, T, Suba, K, Spigelman, A, Wu, Y, MacDonald, P, Wenstedt Asterholm, I, Magnussen, T, Christensen, M, Visboll, T, Salem, V, Knop, F, Rorsman, P, Lowell, B, Briant, L
Format:	Journal article
Language:	English
Published:	eLife Sciences Publications 2021

Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

Similar Items